

IMMUNOTHERAPY BRIDGE

Naples

December 4th - 5th 2019

SCIENTIFIC COORDINATOR

Paolo A. Ascierto - Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy, National Cancer Institute, "Fondazione G. Pascale", Naples, Italy

SCIENTIFIC RATIONAL

Over the last few years, an extensive research has improved our understanding of tumour immunology and enabled the development of novel treatments that can harness the patient's immune system and prevent immune escape.

Through numerous clinical trials and real-world experience, a large amount of evidence of the potential for long-term survival with immunotherapy agents has been accumulated in various types of malignancy, starting from melanoma to extend to other tumours.

The results of these studies have also highlighted a number of recurring observations with immuno-oncology agents, including their potential for clinical application across a broad patient population and for both conventional and unconventional response patterns.

The clinical success of immune checkpoint blockade with anti-cytotoxic T-lymphocyte-associated antigen (CTLA)-4 and anti-programmed death (PD)-1/PD-ligand (L)1 inhibitor in melanoma and other cancers has encouraged increasing development of other immunotherapies, particularly monoclonal antibodies with other immune targets, adoptive cell transfer and vaccines. It has been estimated that there are over 3000 immuno-oncology trials ongoing, targeting hundreds of disease and immune pathways. Study results have highlighted a number of recurring observations, including the immunotherapy potential for clinical application across a broad patient population and for both conventional and unconventional response patterns.

The successes of the immune-oncology is strongly correlated with the immune system ability of "memory" and adaptability, to improve the time of survival and without selecting resistant form of tumoral cells. Another advantage is that the efficacy of immunotherapies does not seem to be particularly influenced by histology and mutations.

First session of the congress will be jointly organized with the Society for Immunotherapy of Cancer (SITC) and dedicated to the evolving topics on cancer immunotherapy (e.g. MUSC: Successes and Failures in Cell Therapies for Solid Tumors, Successes and Failures in Checkpoint Blockade and Costimulation and Successes and Failures in Cancer Vaccination).

Hence, the state of the art of immunotherapy from the clinical point of view in various types of malignancies will be exhaustively discussed (lung, head and neck, ovarian, breast, prostate, bladder, gastrointestinal tract

3P Solution S.r.l. a socio unico. Sede Legale: via Marradi 3, 20123 Milano.

Capitale sociale: 10.000,00€ iv. P.IVA/CF 06860060968 Iscrizione REA MI n.1919426. Provider Standard n. 327 dal 15 ottobre 2012

Sistema di gestione per la qualità secondo la Norma **UNI EN ISO 9001:2015** per progettazione ed erogazione dei servizi per la Formazione Continua in Sanità. Certificazione CSQA n. 23887

and hematologic malignancies) and on targeting cancer through stimulation of innate immunity with intratumorals.

Conclusions will be drawn after the “Great Debate” session, where counterpoint views from leading experts on specific controversial clinical issues will be presented and discussed from different points of view:

- Immunoscore in clinical practice?
- Use of CAR-T in solid tumors?
- Is ADCC important for anti-CTLA-4 MoA?
- The brain is just another organ?
- Microbiota or Nutrition?
- Is chemotherapy immunostimulatory or immunosuppressive?

In order to disclose and stimulate the discussion of new approaches and strategies in the field of immunotherapy and based on the increasing success of “Immunotherapy Bridge” events over the years, a panel of international faculty will join the congress that will be held in December 2019.

Presidents of the event are Paolo A. Ascierto (National Cancer Institute, “Fondazione G. Pascale”, Naples, Italy), Lisa H. Butterfield (Parker Institute for Cancer Immunotherapy Research Center, San Francisco, California, USA) and Igor Puzanov (Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA), who will gather with the international faculty members in an interactive atmosphere which stimulates discussion and exchange of their experience regarding the most recent advances in research and clinical management of the immunotherapy of cancer.

PRELIMINARY SCIENTIFIC PROGRAM

**Invited/To be invited faculty*

***Not included on CME accredited program*

December 4th, 2019

08:30 09:30 Registration**

09:30 09:45 Introduction and objectives, *Paolo A. Ascierto*

SITC Session - Mechanisms of Success and Failure in Immunotherapy

Chairpersons: Lisa H. Butterfield, Samir Khleif

09:45 10:05 MUSC: Successes and Failures in Cell Therapies for Solid Tumors, *Chrystal Paulos*

10:05 10:25 Leveraging Multi-Omic Data to Accelerate Translational Impact at the Parker Institute for Cancer Immunotherapy, *Daniel Wells*

10:25 10:45 Successes and Failures in Checkpoint Blockade and Costimulation, *Yana Najjar*

10:45 11:05 Successes and Failures in Cancer Vaccination, *Lisa H. Butterfield*

11:05 11:20 Discussion

11:20 11:35 Break**

11:35 12:25 Oral Communications (three slots of 15' each)

12:25 13:25 Lecture – Urothelial Cancer, *TBD**

13:25 14:10 Lunch**

3P Solution S.r.l. a socio unico. Sede Legale: via Marradi 3, 20123 Milano.

Capitale sociale: 10.000,00€ iv. P.IVA/CF 06860060968 Iscrizione REA MI n.1919426. Provider Standard n. 327 dal 15 ottobre 2012

Sistema di gestione per la qualità secondo la Norma **UNI EN ISO 9001:2015** per progettazione ed erogazione dei servizi per la Formazione Continua in Sanità. Certificazione CSQA n. 23887



Session 2 - Trends in immunotherapy

Chairpersons: **Sandro Pignata, John Haanen**

- 14:10 15:10 Symposium – Immunotherapy GU and Neck
*Paolo A. Ascierto, TBD**
- 15:10 15:30 Lung (title to be defined), *Marina Garassino**
- 15:30 15:50 Using neoadjuvant trials to drive progress in H&N cancer immunotherapy, *Robert Ferris*
- 15:50 16:10 Ovarian (title to be defined), *Adekunle Odunsi*
- 16:10 16:30 Breast Cancer Immunotherapy: The Time Has Come, *Leisha Emens*
- 16:30 16:45 Break**
- 16:45 17:05 Implications of immunotherapy treatment in the adjuvant setting, *Paul Nathan*
- 17:05 17:25 Radiation and immunotherapy in breast cancer, *Silvia Formenti*
- 17:25 17:45 Primary and secondary mechanisms of immunotherapy resistance, *Jerome Galon*
- 17:45 18:15 Lecture “Merkel Cell” (title to be confirmed), *Paolo A. Ascierto*
- 18:15 18:45 Oral Communications (two slots of 15' each)
- 18:45 19:00 Discussion and conclusions, *Sandro Pignata, John Haanen*

December 5th, 2019

Session 3 - Drivers of immune responses

Chairpersons: **Volkmar Nuessler*, Alfredo Budillon**

- 09:00 09:20 Prostate (title to be defined), *Akash Patnaik*
- 09:20 09:40 Checkpoint Blockade and Immune Homeostasis in the Gastrointestinal Tract, *Michael Dougan*
- 09:40 10:00 Any role for immunotherapy in the treatment of hepatocellular carcinoma?, *Bruno Daniele*
- 10:00 10:20 Driving up immunotherapy response rates in lymphomas, *John Timmerman*
- 10:20 10:35 Break**
- 10:35 10:55 The host genetic factors as modulators of melanoma immunotherapy outcomes, *Tomas Kirchhoff*
- 10:55 11:15 Targeting cancer through stimulation of innate immunity with intratumoral therapies, *Filip Janku*
- 11:15 11:35 The role of metabolic changes in the RCC carcinogenesis and therapy, *Brad Reinfeld*
- 11:35 12:20 Oral Communications (three slots of 15' each)
- 12:20 12:30 Discussion
- 12:30 13:30 Symposium – Immunotherapy in non-melanoma skin cancer: updates and new perspective
*Paolo A. Ascierto, Claus Garbe**
- 13:30 14:15 Lunch**

3P Solution S.r.l. a socio unico. Sede Legale: via Marradi 3, 20123 Milano.

Capitale sociale: 10.000,00€ iv. P.IVA/CF 06860060968 Iscrizione REA MI n.1919426. Provider Standard n. 327 dal 15 ottobre 2012
Sistema di gestione per la qualità secondo la Norma **UNI EN ISO 9001:2015** per progettazione ed erogazione dei servizi per la
Formazione Continua in Sanità. Certificazione CSQA n. 23887



“Great Debate” Session

Chairpersons: Paolo A. Ascierto, Igor Puzanov

- 14:15 14:45 Immunoscore in clinical practice: Yes or Not?
Jerome Galon vs Carlo Bifulco
- 14:45 14:55 Discussion
- 14:55 15:25 Use of CAR-T in solid tumors: Yes or Not?
Adekunle Odunsi vs TBD**
- 15:25 15:35 Discussion
- 15:35 16:05 Is ADCC important for anti-CTLA-4 MoA: Yes or Not?
*Sergio Quezada vs TBD**
- 16:05 16:15 Discussion
- 16:15 16:30 Break**
- 16:15 16:45 The brain is just another organ: Yes or Not?
Hussein Tawbi vs Hideho Okada
- 16:45 16:55 Discussion
- 16:55 17:25 Microbiota or Nutrition?
Giorgio Trinchieri vs Jennifer Mcquade
- 17:25 17:35 Discussion
- 17:35 18:05 Is chemotherapy immunostimulatory or immunosuppressive?
Guido Kroemer vs Samir Khleif
- 18:05 18:15 Discussion
- 18:15 18:25 Conclusions, *Paolo A. Ascierto, Lisa H. Butterfield, Igor Puzanov*

PRESIDENCY

Paolo A. Ascierto - Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy, National Cancer Institute, “Fondazione G. Pascale”, Naples, Italy

Lisa H. Butterfield - Research Center Vice President, Parker Institute for Cancer Immunotherapy and Adjunct Professor of Microbiology and Immunology, University of California, San Francisco, California, US

Igor Puzanov - Director, Early Phase Clinical Trials Program, Chief of Melanoma, Co-Leader, CCSG Experimental Therapeutics Program, Professor of Oncology, Department of Medicine, Roswell Park Comprehensive Cancer Center, Developmental Therapeutics, Buffalo, New York, USA

SCIENTIFIC BOARD

Sanjiv S. Agarwala - Professor & Chief, Haematology & Oncology, St Luke’s Cancer Center & Temple University, Bethlehem, Pennsylvania, US

Paolo A. Ascierto - Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy, National Cancer Institute, “Fondazione G. Pascale”, Naples, Italy

3P Solution S.r.l. a socio unico. Sede Legale: via Marradi 3, 20123 Milano.

Capitale sociale: 10.000,00€ iv. P.IVA/CF 06860060968 Iscrizione REA MI n.1919426. Provider Standard n. 327 dal 15 ottobre 2012
Sistema di gestione per la qualità secondo la Norma **UNI EN ISO 9001:2015** per progettazione ed erogazione dei servizi per la
Formazione Continua in Sanità. Certificazione CSQA n. 23887



Carlo Bifulco - Medical Director of Oncological Molecular Pathology and Pathology Informatics, Providence Oregon Regional Laboratory and Earle A. Chiles Research Institute, Portland, Oregon, US

Lisa H. Butterfield - Research Center Vice President, Parker Institute for Cancer Immunotherapy and Adjunct Professor of Microbiology and Immunology, University of California, San Francisco, California, US

Corrado Caracò - Director of Department Melanoma, Soft Tissue, Muscle-Skeletal and Head-Neck, National Cancer Institute "Fondazione G. Pascale", Naples, Italy

Sandra Demaria - Professor of Pathology and Laboratory Medicine, Professor of Radiation Oncology and Adjunct Professor at Department of Pathology, Weill Cornell Medical College and NYU School of Medicine, New York City, New York, US

Reinhard Dummer - Professor of Dermatology, University of Zurich Hospital, Department of Dermatology, Zurich, Switzerland

Bernard A. Fox - Chief of Laboratory of Molecular and Tumor Immunology, Robert W. Franz Cancer Research Center in the Earle A. Chiles Research Institute at Providence Cancer Center, Portland, Oregon, US

Jerome Galon - Research Director, National Institute of Health and Medical Research (INSERM), Paris, France

Claus Garbe - University Professor of Dermatology, Division of Dermatologic Oncology Department of Dermatology, Eberhard- Karls University Tuebingen, Germany

Omid Hamid - Chief of Research/ Immuno-Oncology and Co-Director, Cutaneous Malignancy Program, The Angeles Clinic and Research Institute, Los Angeles, California, USA

Giuseppe Masucci - Professor, Department of Oncology-Pathology, Karolinska Institute, Stockholm, Sweden

Giuseppe Palmieri - President Italian Melanoma Intergroup (IMI), Head of Unit of Cancer Genetics, Institute of Biomolecular Chemistry (ICB), National Research Council (CNR), Sassari, Italy

Michael Postow - Assistant Professor of Medicine, Memorial Sloane Kettering Cancer Center, New York City, New York, USA

Igor Puzanov - Director, Early Phase Clinical Trials Program, Chief of Melanoma, Co-Leader, CCSG Experimental Therapeutics Program, Professor of Oncology, Department of Medicine, Roswell Park Comprehensive Cancer Center, Developmental Therapeutics, Buffalo, New York, USA

Magdalena Thurin - Program Director, Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, NCI, NIH, Rockville, Maryland, USA

Tara Withington - Executive Director of Society of Immunotherapy for Cancer (SITC), Milwaukee, Wisconsin, USA

INVITED FACULTY

Paolo A. Ascierto - Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy, National Cancer Institute, "Fondazione G. Pascale", Naples, Italy

Carlo Bifulco - Medical Director of Oncological Molecular Pathology and Pathology Informatics, Providence Oregon Regional Laboratory and Earle A. Chiles Research Institute, Portland, Oregon, US

Alfredo Budillon - Director Experimental Pharmacology Unit, Department of Translational Research, National Cancer Institute "Fondazione G. Pascale", Naples, Italy

3P Solution S.r.l. a socio unico. Sede Legale: via Marradi 3, 20123 Milano.

Capitale sociale: 10.000,00€ iv. P.IVA/CF 06860060968 Iscrizione REA MI n.1919426. Provider Standard n. 327 dal 15 ottobre 2012
Sistema di gestione per la qualità secondo la Norma **UNI EN ISO 9001:2015** per progettazione ed erogazione dei servizi per la
Formazione Continua in Sanità. Certificazione CSQA n. 23887



Lisa H. Butterfield - Research Center Vice President, Parker Institute for Cancer Immunotherapy and Adjunct Professor of Microbiology and Immunology, University of California, San Francisco, California, US

Bruno Daniele - Director Clinical Oncology Unit, Rummo Hospital, Benevento, Italy

Michael Dougan - Gastroenterology, Massachusetts General Hospital, Boston, Massachusetts, US

Leisha Emens - Professor of Medicine, UPMC Hillman Cancer Center/Magee Women's Hospital, Director of Translational, Immunotherapy for the Women's Cancer Research Center, Co-Leader, Hillman Cancer Immunology/Immunotherapy Program, Pittsburgh, Pennsylvania, US

Robert Ferris - Director UPMC Hillman Cancer Center, Hillman Professor of Oncology, Associate Vice-Chancellor for Cancer Research, Co-Director Tumor Microenvironment Center, Professor of Otolaryngology, of Immunology, and of Radiation Oncology, Pittsburgh, Pennsylvania, US

Silvia Formenti - Chairman of Radiation Oncology - Weill Cornell Medical College, New York City, New York, US

Jerome Galon - Research Director, National Institute of Health and Medical Research (INSERM), Paris, France

Marina Garassino – Director Division of Thoraco-Pulmonary Medical Oncology, IRCCS Foundation National Cancer Institute, Milan, Italy

John B. Haanen - Head of the Division of Medical Oncology and Staff Scientist in the Division of Immunology, Professor of Translational Immunotherapy of Cancer at Leiden University Medical Centre, Netherlands Cancer Institute, Amsterdam, The Netherlands

Filip Janku - Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, US

Samir N. Khleif - Director of The Loop Immuno-Oncology Laboratory, Biomedical Scholar and Professor of Oncology, Georgetown University Medical School, Washington, DC, US

Tomas Kirchhoff - Associate Professor, Department of Population Health Associate Professor, Department of Environmental Medicine, Perlmutter Cancer Center, New York City, New York, US

Guido Kroemer – Centre de Recherche des Cordeliers, Paris, France

Jennifer Mcquade - Assistant Professor, Department of Melanoma Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Yana Najjar - Assistant Professor of Medicine, Division of Hematology-Oncology, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, US

Paul Nathan - Consultant Medical Oncologist, Mount Vernon Cancer Centre, Northwood, Middlesex, UK

Volkmar Nuessler - Associate Professor in Hematology and Oncology, Tumor Center, CCC Munchen Comprehensive Cancer Centre, Munich, Germany

Adekunle Odunsi - Cancer Center Deputy Director, The M. Steven Piver Professor and Chair, Department of Gynaecologic Oncology, Executive Director, Center for Immunotherapy, Roswell Park Comprehensive Cancer Center, Buffalo, New York, US

Hideho Okada - Professor and Director Brain Tumor Immunotherapy Center in Neurological Surgery, University of California San Francisco, Parker Institute for Cancer Immunotherapy, San Francisco, California, US

Akash Patnaik - Assistant Professor of Medicine, Hematology and Oncology, The University of Chicago Medicine, Chicago, Illinois, US

3P Solution S.r.l. a socio unico. Sede Legale: via Marradi 3, 20123 Milano.

Capitale sociale: 10.000,00€ iv. P.IVA/CF 06860060968 Iscrizione REA MI n.1919426. Provider Standard n. 327 dal 15 ottobre 2012
Sistema di gestione per la qualità secondo la Norma **UNI EN ISO 9001:2015** per progettazione ed erogazione dei servizi per la
Formazione Continua in Sanità. Certificazione CSQA n. 23887



Chrystal M. Paulos - Associate Professor and Endowed Peng Chair, Department of Microbiology and Immunology Hollings Cancer Center, Medical University of South Carolina (MUSC), Charleston, South Carolina, US

Sandro Pignata - Head of the Uro-Gynaecological Department, National Cancer Institute "Fondazione G. Pascale", Naples, Italy

Igor Puzanov - Director, Early Phase Clinical Trials Program, Chief of Melanoma, Co-Leader, CCSG Experimental Therapeutics Program, Professor of Oncology, Department of Medicine, Roswell Park Comprehensive Cancer Center, Developmental Therapeutics, Buffalo, New York, USA

Sergio Quezada - Professor of Cancer Immunology and Immunotherapy at University College London Cancer Institute, London, UK

Brad Reinfeld - Vanderbilt School of Medicine, Graduate Program Cancer Biology, Nashville, Tennessee, US

Hussein Tawbi - Associate Professor, Director of Melanoma Clinical Research & Early Drug Development, Melanoma Medical Oncology, Investigational Cancer Therapeutics, UT MD Anderson Cancer Center, Houston, Texas, US

John Timmerman - Professor of Medicine, Division of Hematology-Oncology, David Geffen School of Medicine at UCLA, UCLA Medical Center, Los Angeles, CA, US

Giorgio Trinchieri - NIH Distinguished Investigator, Director, Cancer and Inflammation Program (CIP), Center for Cancer Research, NCI, NIH, Bethesda, Maryland, US

Daniel Wells - Senior Data Scientist, Parker Institute for Cancer Immunotherapy, University of California, San Francisco, California, US

3P Solution S.r.l. a socio unico. Sede Legale: via Marradi 3, 20123 Milano.

Capitale sociale: 10.000,00€ iv. P.IVA/CF 06860060968 Iscrizione REA MI n.1919426. Provider Standard n. 327 dal 15 ottobre 2012
Sistema di gestione per la qualità secondo la Norma **UNI EN ISO 9001:2015** per progettazione ed erogazione dei servizi per la
Formazione Continua in Sanità. Certificazione CSQA n. 23887

